Additional Information
Market: OTCQB
Sector: Medical
EPIC: PBIO
1 year chart
1 day chart
Pressure BioSciences
www.pressurebiosciences.com

Pressure BioSciences, Inc. is company focused on the development and commercialization of a novel, enabling, platform technology called pressure cycling technology ("PCT"). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions.

Pressure BioSciences bolsters board of directors with addition of Dr. Mickey Urdea

12th Feb 2013, 11:10 am by Deborah Bacal
Dr. Urdea, who has a 30-year career in human diagnostics through a variety of capacities, will be a Class III board member. His term of office will expire at the 2014 annual meeting of shareholders. In addition to his responsibilities on the board, Dr. Urdea will lead the company’s scientific advisory board. Dr. Urdea, who has a 30-year career in human diagnostics through a variety of capacities, will be a Class III board member. His term of office will expire at the 2014 annual meeting of shareholders. In addition to his responsibilities on the board, Dr. Urdea will lead the company’s scientific advisory board.

Pressure BioSciences (OTCQB:PBIO) says it has appointed Dr. Mickey Urdea to its board of directors, filling the vacancy of Wayne Fritzsche, who resigned last week to pursue a full-time management position with the company as it builds out commercially. 

Dr. Urdea, who has a 30-year career in human diagnostics through a variety of capacities, will be a Class III board member. His term of office will expire at the 2014 annual meeting of shareholders. In addition to his responsibilities on the board, Dr. Urdea will lead the company’s scientific advisory board. 

The new board member has been involved in the discovery of new biomarkers, diagnostic test development, manufacturing and marketing. 

He founded and is a managing partner for Halteres Associates, a biotechnology consulting firm, and also served as CEO of Tethys Bioscience, a proteomics-based diagnostics company involved in preventative personalized medicine. 

Tethys’ first product was the protein-based PreDx Diabetes Risk Score Test, which was introduced in 2008. 

“Mickey’s technical experience, gained from bench scientist to widely-recognized R&D leader spanning multiple successful cutting-edge technologies, will contribute strongly to the selection and development of key markets for our patented pressure cycling technology (PCT) platform," said Pressure BioSciences' chairman, Jeffrey N. Peterson. 

"His entrepreneurial success in founding and leading nationally-acclaimed companies in biomarker discovery, personalized medicine, and healthcare strategic consulting will be immensely useful as we continue our aggressive PCT commercialization strategy."

The U.S. company operates in the growing biosample preparation market for life science research, which according to a recent report by AMI Research, was valued at $3.6 billion in 2011 and growing at an average of 18.5% annually through 2016. 

In 2012, the company began to aggressively commercialize its patented pressure cycling technology (PCT), which uses rapid and repeating cycles of hydrostatic pressure at controlled temperatures to extract cell components in the preparation of a biological sample - such as DNA, RNA, and proteins from humans, animals and plants - for further study.

Through the second half of the year, the company entered into various distribution agreements and began to build its global brand.

In November, Pressure BioSciences inked a two-way strategic marketing, selling and distribution agreement with UK-based biomedical product provider Constant Systems, with the deal to expand Pressure's international reach into 12 additional countries. 

This deal followed three global distribution deals back in the summer, and a deal with biotech services giant Thermo Fisher's (NYSE:TMO) Cole-Parmer unit, which agreed to carry the company's PBI Shredder SG3 system. 

The company's PCT platform can also be used in several fields aside from the life sciences arena, with Pressure BioSciences already gaining traction in forensic sciences. 

Earlier this year, the Florida International University was awarded a near $350,000 grant to improve rape case DNA testing using Pressure BioSciences' PCT platform. The FIU was awarded the grant from the Office of Justice Programs of the Department of Justice (DOJ).

The goal of the grant is to develop a faster and more accurate method of processing DNA evidence for rape prosecutions. The PCT technology permits the user to selectively burst open and extract DNA from the perpetrator’s sperm cells, while leaving the victim’s own cells in the swab sample unbroken. 

This new procedure is expected to be complete by the fourth quarter of this year.

Aside from forensics, its PCT-based products can also be used for the key $2 billion target market of mass spectrometry, an analytical technique used to determine the characteristics of molecules, to biomarker discovery, and counter-bioterrorism, among other uses. 

“Since being introduced to PCT just three months ago, I have become fascinated with the current applications and extensive future potential uses of this cutting-edge technology platform," said Dr. Urdea in the statement. 

"I believe PCT has the potential to gain widespread adoption and become a vital sample preparation tool to research and clinical laboratories worldwide."

Previously, Dr. Urdea was also business head of the molecular diagnostics group and chief scientific officer at Bayer Diagnostics, and was a member of the Bill and Melinda Gates Foundation Diagnostic Forum.

He is an author on nearly 200 peer-reviewed scientific publications, nearly 300 abstracts and international scientific presentations, and more than 100 issued and pending patents. 

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here